• Skip to main content
  • Skip to header right navigation
  • Skip to site footer

Log in
  • Search
    • Search All SAGES Content
    • Search SAGES Guidelines
    • Search the Video Library
    • Search the Image Library
    • Search the Abstracts Archive
www.sages.org

SAGES

Reimagining surgical care for a healthier world

  • Home
    • Search
    • SAGES Home
    • SAGES Foundation Home
  • About
    • Awards
    • Who Is SAGES?
    • Leadership
    • Our Mission
    • Advocacy
    • Committees
      • SAGES Board of Governors
      • Officers and Representatives of the Society
      • Committee Chairs and Co-Chairs
      • Committee Rosters
      • SAGES Past Presidents
  • Meetings
    • SAGES NBT Innovation Weekend
    • SAGES Annual Meeting
      • 2026 Scientific Session Call for Abstracts
      • 2026 Emerging Technology Call for Abstracts
    • CME Claim Form
    • SAGES Past, Present, Future, and Related Meeting Information
    • SAGES Related Meetings & Events Calendar
  • Join SAGES!
    • Membership Application
    • Membership Benefits
    • Membership Types
      • Requirements and Applications for Active Membership in SAGES
      • Requirements and Applications for Affiliate Membership in SAGES
      • Requirements and Applications for Associate Active Membership in SAGES
      • Requirements and Applications for Candidate Membership in SAGES
      • Requirements and Applications for International Membership in SAGES
      • Requirements for Medical Student Membership
    • Member Spotlight
    • Give the Gift of SAGES Membership
  • Patients
    • Join the SAGES Patient Partner Network (PPN)
    • Patient Information Brochures
    • Healthy Sooner – Patient Information for Minimally Invasive Surgery
    • Choosing Wisely – An Initiative of the ABIM Foundation
    • All in the Recovery: Colorectal Cancer Alliance
    • Find A SAGES Surgeon
  • Publications
    • Clinical / Practice / Training Guidelines, Statements, and Standards of Practice
    • Sustainability in Surgical Practice
    • SAGES Stories Podcast
    • Patient Information Brochures
    • Patient Information From SAGES
    • TAVAC – Technology and Value Assessments
    • Surgical Endoscopy and Other Journal Information
    • SAGES Manuals
    • MesSAGES – The SAGES Newsletter
    • COVID-19 Archive
    • Troubleshooting Guides
  • Education
    • Wellness Resources – You Are Not Alone
    • Avoid Opiates After Surgery
    • SAGES Subscription Catalog
    • SAGES TV: Home of SAGES Surgical Videos
    • The SAGES Safe Cholecystectomy Program
    • Masters Program
    • Resident and Fellow Opportunities
      • MIS Fellows Course
      • SAGES Robotics Residents and Fellows Courses
      • SAGES Free Resident Webinar Series
      • Fluorescence-Guided Surgery Course for Fellows
      • Fellows’ Career Development Course
    • SAGES S.M.A.R.T. Enhanced Recovery Program
    • SAGES @ Cine-Med Products
      • SAGES Top 21 Minimally Invasive Procedures Every Practicing Surgeon Should Know
      • SAGES Pearls Step-by-Step
      • SAGES Flexible Endoscopy 101
    • SAGES OR SAFETY Video Activity
  • Opportunities
    • Fellowship Recognition Opportunities
    • SAGES Advanced Flexible Endoscopy Area of Concentrated Training (ACT) SEAL
    • Multi-Society Foregut Fellowship Certification
    • Research Opportunities
    • FLS
    • FES
    • FUSE
    • Jobs Board
    • SAGES Go Global: Global Affairs and Humanitarian Efforts
  • OWLS/FLS
You are here: Home / Abstracts / Oncological outcome of 90 patients after transanal totalmesorectal excision for rectal cancer: short term follow up.

Oncological outcome of 90 patients after transanal totalmesorectal excision for rectal cancer: short term follow up.

Jacqueline van Laarhoven, MD, PhD1, Borja DeLacy, MD2, Romina Pena, MD2, María Arroyave, MD3, María Fernández-Hevia, MD2, Gabriel Díaz del Gobbo, MD2, Antonio Lacy, MD, Professor2. 1Jeroen Bosch Ziekenhuis, 2Hospital Clinic Barcelona, 3Clinica SOMER

Introduction: The transanal total mesorectal excision (taTME) seems to be a valid alternative to the often technical difficult performance of open or laparoscopic TME. Pathological results seem comparible to the laparoscopic or open technique. This study is one of the first studies to show oncological follow up of a large series of patients treated by taTME.

Methods and procedures: All patients with rectal cancer treated at our hospital by taTME between November 2011 and June 2016 were prospectively included in a standardized database. Patients with a minimal follow-up of 24 months were included in this analysis. High-, mid- and low rectal cancer were included in this analysis, patients with a preoperative T4 tumor were excluded. Patients periodically visited the outpatient clinic with analysis of serum carcinoembryonic antigen concentrations, colonoscopy, thoracic and abdominal computed tomography to determine recurrence of disease.

Results: A total of 90 patients were included in this analysis. At time of surgery patients had a median age of 67.5 years (range 38 – 85) and 64.4% (n=58) were male. Patients were classified as ASA I in 5.6%, ASA II in 83.3% and ASA III in 11.1%. Neoadjuvant chemoradiotherapy was administered in 56.7% (n=51) of the patients and one patient only received radiotherapy. Tumor was located in the high-, mid- and low rectum in respectively 24.4%, 52.2% and 23.3%. Postoperative pathological staging showed complete remission in 11.1%, pT1 in 8.9%, pT2 in 27.8%, pT3 in 46.7%, pT4 in 3.3%, pTis in 2.2%. Furtermore, pathological results showed N0 in 67.8%, N1 in 22.2%, N1c in 1.1% and Nx in 2.2%. CRM was <1mm in 8.9% and the mesorectal quality was complete in 98.9%.The included patients had a median follow up of 34.5 months (range 24.0 – 56.0). Of these patients 80% (n=72) had no recurrent disease, 16.7% (n=15) had recurrent disease and three patients had died with recurrent disease. Median time of overall recurrent disease was 19.5 months (range 4.0 – 37.0). A total of 15.6% of the patients had systemic recurrent disease, with a median time of 17.0 months (range 4.0 – 33.0). A total of 6.7% of the patients had locoregional recurrent disease, with a median time of 24.0 months (range 10.0 – 37.0).

Conclusion: Short term oncological outcomes after taTME are comparible to outcomes after laparoscopic TME.


Presented at the SAGES 2017 Annual Meeting in Houston, TX.

Abstract ID: 80488

Program Number: P188

Presentation Session: Poster (Non CME)

Presentation Type: Poster

33

Share this:

  • Click to share on X (Opens in new window) X
  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on LinkedIn (Opens in new window) LinkedIn
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Mastodon (Opens in new window) Mastodon
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on Bluesky (Opens in new window) Bluesky

Related


sages_adbutler_leaderboard

Hours & Info

11300 West Olympic Blvd, Suite 600
Los Angeles, CA 90064

1-310-437-0544

[email protected]

Monday – Friday
8am to 5pm Pacific Time

Find Us Around the Web!

  • Bluesky
  • X
  • Instagram
  • Facebook
  • YouTube

Copyright © 2025 · SAGES · All Rights Reserved

Important Links

Healthy Sooner: Patient Information

SAGES Guidelines, Statements, & Standards of Practice

SAGES Manuals